Blog
RSS FeedPosted by Michael Wonder on 14 Feb 2021
Assessment of FDA and EMA approved systemic oncology therapies and clinically meaningful improvements in quality of life
11 February 2021 - Are oncology therapies recently approved by the US FDA and the EMA associated with clinically meaningful improvements ...
Posted by Michael Wonder on 29 Sep 2020
The estimation of health state utility values in rare diseases: overview of existing techniques
25 September 2020 - There are several techniques for estimating health state utility values, each of which presents pros and cons ...
Posted by Michael Wonder on 12 Aug 2020
What is it going to be, TTO or SG? A direct test of the validity of health state valuation
12 August 2020 - It has been suggested that time trade-off yields more accurate health state valuations, because time trade-off ...
Posted by Michael Wonder on 12 May 2020
A comparison of the EQ-5D-3L and EQ-5D-5L
12 May 2020 - Previous studies have found the EQ-5D-5L to have superior measurement properties but no study has compared ...
Posted by Michael Wonder on 17 Mar 2020
Explaining health state utility assessment
17 March 2020 - Health state utilities are used to provide quantitative measures of how strongly a person values a certain ...
Posted by Michael Wonder on 12 Feb 2020
Researchers wanted to study the public’s views of health-related quality of life
12 February 2020 - Applications close on Wednesday 4 March 2020 ...
Posted by Michael Wonder on 28 Oct 2019
NICE to support new valuation study for England for EQ-5D-5L questionnaire
24 October 2019 - Study will measure public’s preference for different health states. ...
Posted by Michael Wonder on 13 Jan 2019
The impact of moving from the EQ-5D-3L to the -5L in NICE technology appraisals
11 January 2019 - The EQ-5D instrument is NICE’s preferred measure of health-related quality of life in adults. ...
Posted by Michael Wonder on 05 Oct 2018
Evaluating progression-free survival as a surrogate outcome for health-related quality of life in oncology
1 October 2018 - Progression-free survival has become a commonly used outcome to assess the efficacy of new cancer drugs. However, ...
Posted by Michael Wonder on 27 Sep 2018
Differentiation of health-related quality of life outcomes between five disease areas: results from an international survey of patients
25 September 2018 - Health-related quality of life data generated by generic, preference-based instruments are highly demanded in health policy decision ...
Posted by Michael Wonder on 13 Jun 2018
Metastatic breast cancer: highly selective post-hoc analysis rather than complete publication of quality of life data
13 June 2018 - IQWiG employees criticise the publication practice of PALOMA-2 study authors. ...
Posted by Michael Wonder on 20 May 2018
3L, 5L, What the L? A NICE conundrum
20 May 2018 - For many years, NICE has recommended use of the EQ-5D-3L and its value set for the UK. ...
Posted by Michael Wonder on 27 Apr 2018
What is the evidence for the performance of generic preference-based measures? A systematic overview of reviews
27 April 2018 - Finch assessed the evidence on the validity and responsiveness of five commonly used preference-based instruments, the ...
Posted by Michael Wonder on 14 Nov 2017
The “utility” in composite outcome measures
14 November 2017 - Measuring what is important to patients. ...
Posted by Michael Wonder on 10 Nov 2017
Quality of life: an important element of treatment value
9 November 2017 - In the era of platinum-based chemotherapy, attempts to improve the quality of life of patients with advanced ...